^
Association details:
| Biomarker: | CLDN18.2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | IBI-343 (Topoisomerase I inhibitor, CLDN18.2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer
Published date:
05/06/2024
Excerpt:
...the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343 as monotherapy for the treatment of claudin18.2-positive advanced gastric/gastro-esophageal junction adenocarcinoma (GC) patients who have progressed after at least 2 lines of prior systematic treatments.
